cytarabine has been researched along with homoharringtonine in 74 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.05) | 18.7374 |
| 1990's | 7 (9.46) | 18.2507 |
| 2000's | 19 (25.68) | 29.6817 |
| 2010's | 32 (43.24) | 24.3611 |
| 2020's | 13 (17.57) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ahmed, T; Arlin, Z; Baskind, P; Chun, H; Cook, P; Feldman, E; Mittelman, A; Puccio, C | 1 |
| Gao, RL; Jin, JM; Ma, FS | 1 |
| Dulmadge, DA; Griswold, DP; Laster, WR; Wilkoff, LJ | 1 |
| Anderlini, P; Kantarjian, HM; O'Brien, S; Talpaz, M | 1 |
| Cortes, JE; Kantarjian, H; Talpaz, M | 1 |
| Baccarani, M; Damiani, D; Manfroi, S; Michelutti, A; Ottaviani, E; Russo, D; Tosi, P; Tura, S; Visani, G | 1 |
| Cheson, BD | 1 |
| Ferrini, PR; Santini, V | 1 |
| Bian, S; Luo, M; Xue, Y | 1 |
| Cheson, B; Cortes, J; Gajewski, J; Giles, FJ; Kantarjian, HM; Mallard, S; Murgo, A; O'Brien, S; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S | 1 |
| Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S | 1 |
| Chen, J; Gu, L; Pan, C; Tang, J; Xue, H; Zhao, H | 1 |
| Andreeff, M; Cortes, J; Faderl, S; Freireich, E; Garcia-Manero, G; Giles, F; Kantarjian, HM; Kornblau, S; Mallard, S; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; White, K | 1 |
| Dubrulle, S; Faussat, AM; Legrand, O; Majdak, P; Marie, JP; Marjanovic, Z; Marzac, C; Tang, R | 1 |
| Bloomfield, CD; Karrison, T; Larson, RA; Sher, D; Stock, W; Stone, RM; Yu, D | 1 |
| Chen, ZM; Huang, J; Jiang, DZ; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Tong, HY; Tong, Y; Wang, L; Xu, WL | 1 |
| Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
| Hao, Y; Li, R; Xiao, Z; Xue, H; Yu, M; Zhang, L | 1 |
| Cao, XM; Chen, YX; He, AL; Liu, J; Liu, SH; Ma, XR; Wang, FX; Wang, JL; Zhang, WG; Zhao, WH | 1 |
| Bian, S; Liu, S; Meng, Q; Mi, Y; Wang, J; Xue, Y; Yu, W; Zhao, Y | 1 |
| Huang, J; Jiang, DZ; Jin, J; Liu, H; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Tong, HY; Tong, Y; Wang, L | 1 |
| Bloomfield, CD; Deangelo, DJ; Donohue, KA; Hars, V; Larson, RA; Linker, CA; Marcucci, G; Shea, T; Stock, W; Stone, RM | 1 |
| Cao, XM; Chen, YX; He, AL; Liu, J; Ma, XR; Zhang, WG | 1 |
| Chang, H; He, C; Liu, T; Xiang, B; Xu, CG; Xu, J | 1 |
| Chang, CK; He, Q; Li, X; Song, LQ; Su, JY; Wu, LY; Xu, L; Zhang, X; Zhou, LY | 1 |
| Chen, L; Hou, J; Huang, C; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Song, L; Su, J; Wu, L; Xu, L; Zhang, X | 1 |
| Chen, YX; He, AL; Ji, YY; Liu, J; Wang, FX; Wang, JL; Zhang, PY; Zhang, WG; Zhang, WJ; Zhao, XM | 1 |
| Jin, J; Qian, WB; Xu, WL | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Liu, J; Ma, XR; Wang, FX; Zhang, WG | 1 |
| Huang, J; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Song, YP; Tong, HY; Tong, Y; Xu, WL | 1 |
| Chen, J; Gu, L; Liu, Y; Pan, C; Tang, J; Xue, H | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Su, J; Wu, L; Zhang, X | 1 |
| Chen, X; Yang, W; Zhu, X | 1 |
| Fang, LW; Hu, NB; Pan, LJ; Qin, TJ; Wang, JZ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Fang, B; Li, Y; Liu, Y; Song, Y; Zhou, J | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Y; Zhang, Z | 1 |
| Chen, L; Mi, R; Wei, X; Yin, Q | 1 |
| Jin, J; Mai, W; Mao, L; Meng, H; Qian, J; Qian, W; Tong, H; Tong, Y; Yu, W | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 1 |
| Chen, H; Chen, J; Du, G; Han, Q; Liu, C; Sun, M; Wang, W; Wu, L | 1 |
| Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Su, YZ; Sun, NT; Wang, CB; Zhou, Y | 1 |
| Chang, C; Chao, X; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Chen, A; Hu, S; Wang, QF; Yang, J | 1 |
| Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Qin, YZ; Zhu, HH | 1 |
| Fang, L; Hu, N; Lin, Y; Pan, L; Qin, T; Qu, S; Ru, K; Wang, J; Xiao, Z; Xing, R; Xu, Z; Zhang, H; Zhang, Y | 1 |
| Fan, C; Huang, J; Jin, J; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Yu, W | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Wang, FX; Wang, JL; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Jiang, Q; Li, L; Sun, J; Xie, M; Xie, W; Yang, X; Ye, X; Zheng, Y; Zhu, J; Zhu, L; Zhu, M | 1 |
| Cao, J; Chen, C; Chen, W; Ding, NN; Feng, H; Niu, MS; Qiu, TT; Wu, QY; Xu, KL; Zhu, HH | 1 |
| Chen, M; Liu, H; Liu, L; Ren, S; Zhang, H; Zhang, J | 1 |
| Chen, J; Chen, R; Chen, X; Gu, L; Pan, C; Shen, S; Tang, J; Tang, Y; Xue, H | 1 |
| Li, LJ; Yu, K; Zhang, JY | 1 |
| Gu, L; Liu, L; Luo, YH; Wu, HY | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Tao, Y; Wu, D; Wu, L; Xiu, C; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Borthakur, G; Boyer, AD; Huang, R; Huang, X; Ji, D; Jiang, M; Li, F; Luan, S; Tang, G; Xu, Q; You, MJ; Zhang, Z | 1 |
| Jin, J; Li, J; Yu, W; Zhang, X | 1 |
| Fan, Z; Jin, Y; Li, L; Liu, W; Zhang, JY; Zhao, M; Zhou, Y | 1 |
| Dang, FT; Wan, YM; Yang, J; Yang, QJ; Zheng, J | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Braniecki, M; Gok Yavuz, B; Hwang, J; Quigley, JG; Singh, N; Tsoukas, MM | 1 |
| Chen, Q; Chen, Y; Hu, J; Li, J; Li, X; Mao, Y; Shen, Y; Sheng, Y; Wang, L; Weng, X; Wu, J; Wu, M; You, J; Zhang, Y; Zhao, H; Zheng, Y | 1 |
| Guo, Z; Liu, L; Liu, P; Ren, X; Wang, F; Xu, W; Xu, Y; Zhang, H; Zhang, S; Zheng, L | 1 |
| Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B | 1 |
| Chen, J; Fang, Q; Gong, B; Gong, X; Gu, R; Jin, J; Li, Y; Lin, D; Liu, B; Liu, K; Liu, Y; Mi, Y; Qiu, S; Song, Z; Wang, J; Wang, Y; Wei, H; Wei, S; Yang, M; Zhang, G; Zhang, J; Zhou, C | 1 |
| Fang, QY; Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Qiu, SW; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, CX; Zhang, GJ; Zhou, CL | 1 |
| Hou, JX; Hu, YM; Li, SZ; Lin, D; Liu, KQ; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Cao, H; Chen, S; Chen, Y; Dai, Y; Fan, J; Fang, Y; Gao, C; Gao, J; Han, Y; Hu, Q; Huang, P; Jin, J; Ju, X; Li, J; Liang, C; Liang, H; Lin, L; Lin, W; Liu, A; Liu, W; Peng, X; Peng, Y; Qi, P; Shao, J; Shi, X; Tian, X; Wang, J; Wang, L; Wang, T; Wang, X; Wang, Y; Wu, Y; Xiong, H; Xu, L; Yan, M; Yang, L; Yu, H; Yu, J; Zhai, X; Zhang, J; Zhang, L; Zhang, R; Zhang, Y; Zhao, W; Zheng, H; Zhou, M | 1 |
6 review(s) available for cytarabine and homoharringtonine
| Article | Year |
|---|---|
Treatment of myelogenous leukemia: current status and investigational options.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cytarabine; Harringtonines; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Treatment Outcome | 1996 |
Chronic myelogenous leukemia: a review.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cytarabine; Drug Therapy, Combination; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prognosis; Time Factors | 1996 |
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.
Topics: Anthracyclines; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Harringtonines; Homoharringtonine; Humans; Myelodysplastic Syndromes; Pyrimidines; Topotecan | 1998 |
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arginine; Azacitidine; Butyrates; Cholecalciferol; Cytarabine; Harringtonines; Hematopoietic Cell Growth Factors; Heme; Homoharringtonine; Humans; Interferons; Myelodysplastic Syndromes; Retinoids | 1998 |
The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2015 |
HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
20 trial(s) available for cytarabine and homoharringtonine
| Article | Year |
|---|---|
Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 1992 |
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Survival Analysis | 2000 |
A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2003 |
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Drug Administration Schedule; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2009 |
[A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Young Adult | 2009 |
[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2009 |
Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Disease Progression; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Treatment Outcome; Young Adult | 2009 |
[Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Monocytic, Acute; Male; Middle Aged; Treatment Outcome; U937 Cells; Young Adult | 2010 |
Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
Topics: Aclarubicin; Adult; Aged; Cytarabine; Drug Combinations; Female; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2010 |
[Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Young Adult | 2011 |
Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Heart Diseases; Homoharringtonine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Young Adult | 2013 |
Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Topics: Adolescent; Adult; Antigens, CD34; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cell Count; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Hematologic Diseases; Homoharringtonine; Humans; Immunophenotyping; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Remission Induction; Young Adult | 2014 |
Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
Topics: Anthracyclines; China; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Remission Induction | 2019 |
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine | 2019 |
The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Treatment Outcome | 2019 |
Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Remission Induction; Retreatment; Retrospective Studies; Risk Factors; Salvage Therapy; Single-Blind Method; Time Factors; Treatment Failure | 2021 |
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cyclophosphamide; Cytarabine; Daunorubicin; Down-Regulation; Drug Eruptions; Hidradenitis; Homoharringtonine; Humans; Incidence; Leukemia, Myeloid, Acute; Mercaptopurine; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neutrophils; Protein Kinase Inhibitors; Sweat Glands | 2021 |
Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2022 |
Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; East Asian People; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2023 |
48 other study(ies) available for cytarabine and homoharringtonine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Leukemic clonogenic assay and drug sensitivity test of homoharringtonine and cytarabine in acute myeloid leukemia].
Topics: Alkaloids; Bone Marrow; Colony-Forming Units Assay; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Prognosis; Tumor Stem Cell Assay | 1989 |
Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.
Topics: Alkaloids; Animals; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance; Female; Gene Amplification; Harringtonines; Homoharringtonine; Leukemia P388; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Tumor Cells, Cultured; Vincristine | 1989 |
High remission induction (traditional sino-western HOAP) regimen for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Child; Cytarabine; Drug Therapy, Combination; Female; Harringtonines; Homoharringtonine; Humans; Leukemia; Male; Medicine, Chinese Traditional; Middle Aged; Prednisone; Vincristine | 1980 |
Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Topics: Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Female; Harringtonines; Hematopoietic Stem Cells; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 1997 |
[Study on combined chemosensitivity test in acute non-lymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1998 |
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine | 2001 |
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; Homoharringtonine; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Cytarabine; Cytochromes a; Cytochromes c; Daunorubicin; Down-Regulation; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Protein Biosynthesis; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow; Cytarabine; DNA Primers; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2006 |
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2006 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Metabolic Clearance Rate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis | 2008 |
Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Retrospective Studies; Treatment Outcome | 2008 |
Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis | 2008 |
[HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2008 |
[Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2008 |
A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Drug Administration Schedule; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis | 2009 |
Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, CXCR4; Recurrence | 2011 |
[The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; China; Clinical Chemistry Tests; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Harringtonines; Hematologic Tests; Hepatitis B; Homoharringtonine; Humans; Infant; Leukemia, Myeloid, Acute; Liver Failure; Male; Pancreatitis; Remission Induction; Secondary Prevention | 2011 |
Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk | 2011 |
Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cytarabine; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Piperazines; Pyrimidines | 2011 |
Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Endostatins; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Prognosis; Salvage Therapy; Treatment Outcome | 2012 |
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Decitabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Ribosomal Proteins; Risk Factors; Treatment Outcome; Young Adult | 2012 |
CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Primary distal femur T-cell lymphoma after allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: a rare case report and literature review.
Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Harringtonines; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell; Male; Neoplasm Invasiveness; Transplantation, Homologous | 2014 |
Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Survival Analysis; Treatment Outcome | 2015 |
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cohort Studies; Cytarabine; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocytes; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Thrombocytopenia | 2015 |
Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Case-Control Studies; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Endostatins; Female; Fibroblast Growth Factors; Gene Expression; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; ROC Curve; Treatment Outcome | 2015 |
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oncogene Proteins, Fusion; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Survival Rate; Translocation, Genetic; Young Adult | 2016 |
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Topics: Cytarabine; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Pilot Projects; Remission Induction; Risk; Young Adult | 2016 |
Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Leukemia; Oncogene Proteins, Fusion; Proteolysis; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2016 |
Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Transplantation, Homologous | 2017 |
Clinical characteristics and management of primary granulocytic sarcoma of the breast: A case report.
Topics: Adult; Breast Neoplasms; Cytarabine; Diagnosis, Differential; Female; Homoharringtonine; Humans; Induction Chemotherapy; Mastectomy, Modified Radical; Sarcoma, Myeloid; Sentinel Lymph Node Biopsy; Treatment Outcome | 2019 |
Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma | 2020 |
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Topics: Aclarubicin; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Male; Mutation; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Sulfonamides | 2020 |
Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dasatinib; Daunorubicin; Female; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.
Topics: Adult; Aged; Aminopyridines; Antimetabolites, Antineoplastic; Benzamides; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
Topics: CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Proteins; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Prognosis; Receptors, Colony-Stimulating Factor; Retrospective Studies | 2022 |
[Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2022 |
[Analysis of the efficacy of azacitidine combined with homoharringtonine and cytarabine in induction and salvage therapy of acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Treatment Outcome | 2022 |